INTENSITY THERAPEUTICS, INC. financial data

Symbol
INTS on Nasdaq
Location
Shelton, CT
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 184% % -42%
Debt-to-equity 73% % 79%
Return On Equity -371% % -77%
Return On Assets -215% % -44%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60,064,965 shares 333%
Common Stock, Shares, Outstanding 49,068,621 shares 254%
Entity Public Float $45,300,000 USD 106%
Common Stock, Value, Issued $5,000 USD 400%
Weighted Average Number of Shares Outstanding, Basic 43,042,691 shares 212%
Weighted Average Number of Shares Outstanding, Diluted 43,042,691 shares 212%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $7,250,000 USD -30%
General and Administrative Expense $4,785,000 USD -25%
Operating Income (Loss) $12,035,000 USD 28%
Net Income (Loss) Attributable to Parent $11,736,000 USD 28%
Earnings Per Share, Basic 0 USD/shares -85%
Earnings Per Share, Diluted 0 USD/shares -85%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $7,067,000 USD 154%
Cash, Cash Equivalents, and Short-term Investments $7,100,000 USD
Assets, Current $8,186,000 USD 116%
Operating Lease, Right-of-Use Asset $103,000 USD -20%
Other Assets, Noncurrent $1,296,000 USD -0.15%
Assets $9,585,000 USD 84%
Accounts Payable, Current $1,684,000 USD 212%
Employee-related Liabilities, Current $15,000 USD -98%
Accrued Liabilities, Current $561,000 USD -68%
Liabilities, Current $2,276,000 USD -1.8%
Operating Lease, Liability, Noncurrent $87,000 USD -26%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $2,363,000 USD -2.9%
Retained Earnings (Accumulated Deficit) $75,338,000 USD -18%
Stockholders' Equity Attributable to Parent $7,222,000 USD 160%
Liabilities and Equity $9,585,000 USD 84%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,989,000 USD 54%
Net Cash Provided by (Used in) Financing Activities $328,000 USD 4000%
Net Cash Provided by (Used in) Investing Activities $0 USD -100%
Common Stock, Shares Authorized 135,000,000 shares 0%
Common Stock, Shares, Issued 49,068,621 shares 254%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,661,000 USD -51%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7,067,000 USD 154%
Deferred Tax Assets, Valuation Allowance $16,221,000 USD 35%
Deferred Tax Assets, Gross $16,254,000 USD 35%
Operating Lease, Liability $118,000 USD -19%
Lessee, Operating Lease, Liability, to be Paid $131,000 USD -22%
Operating Lease, Liability, Current $31,000 USD 11%
Lessee, Operating Lease, Liability, to be Paid, Year Two $39,000 USD 5.4%
Lessee, Operating Lease, Liability, to be Paid, Year One $37,000 USD 2.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $13,000 USD -41%
Lessee, Operating Lease, Liability, to be Paid, Year Three $39,000 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $10,235,000 USD 19%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $39,000 USD 0%
Operating Lease, Payments $47,000 USD 0%
Additional Paid in Capital $82,555,000 USD 24%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $33,000 USD -15%
Share-based Payment Arrangement, Expense $2,394,000 USD -9.7%
Interest Expense $0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%